Evidence map›Paper›PMID 36681803›Full record

ReviewMolecular cancer2023

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance.

Pavel Stejskal, Hani Goodarzi, Josef Srovnal, Marián Hajdúch, Laura J van 't Veer, Mark Jesus M Magbanua

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
175citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

175 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. Review
  6. Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

115 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pavel StejskalInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, 779 00, Czech Republic. pavel.stejskal@upol.cz.
Hani GoodarziDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, 94158, USA.
Josef SrovnalInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, 779 00, Czech Republic.
Marián HajdúchInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Olomouc, 779 00, Czech Republic.
Laura J van 't VeerDepartment of Laboratory Medicine, University of California San Francisco, 2340 Sutter Street, San Francisco, CA, USA.
Mark Jesus M MagbanuaDepartment of Laboratory Medicine, University of California San Francisco, 2340 Sutter Street, San Francisco, CA, USA. mark.magbanua@ucsf.edu.

Funding

The Cancer Cell Map Initiative v2.0U54CA274502 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emma Lundberg · 2022 to 2026
$14.2M
Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2017 to 2021
$10.9M
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancerR01CA255442 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, WEN, MAGBANUA, MARK JESUS · 2021 to 2025
$3.3M
An antisense RNA-mediated regulatory program that drives cancer metastasisR01CA240984 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOODARZI, HANI · 2019 to 2023
$2.5M
The RNA structural code underlying pathological regulation of RNA splicing in metastasisR01CA244634 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOODARZI, HANI · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA240984NCI NIH HHS R01 CA244634NCI NIH HHS R01 CA255442NCI NIH HHS U54 CA209891NCI NIH HHS U54 CA274502
6 · The paper itself

Abstract

backgroundDespite advances in early detection and therapies, cancer is still one of the most common causes of death worldwide. Since each tumor is unique, there is a need to implement personalized care and develop robust tools for monitoring treatment response to assess drug efficacy and prevent disease relapse. MAIN BODY: Recent developments in liquid biopsies have enabled real-time noninvasive monitoring of tumor burden through the detection of molecules shed by tumors in the blood. These molecules include circulating tumor nucleic acids (ctNAs), comprising cell-free DNA or RNA molecules passively and/or actively released from tumor cells. Often highlighted for their diagnostic, predictive, and prognostic potential, these biomarkers possess valuable information about tumor characteristics and evolution. While circulating tumor DNA (ctDNA) has been in the spotlight for the last decade, less is known about circulating tumor RNA (ctRNA). There are unanswered questions about why some tumors shed high amounts of ctNAs while others have undetectable levels. Also, there are gaps in our understanding of associations between tumor evolution and ctNA characteristics and shedding kinetics. In this review, we summarize current knowledge about ctNA biology and release mechanisms and put this information into the context of tumor evolution and clinical utility.

conclusionsA deeper understanding of the biology of ctDNA and ctRNA may inform the use of liquid biopsies in personalized medicine to improve cancer patient outcomes.

Indexed as

Cell-Free Nucleic AcidsNeoplasmsNeoplastic Cells, CirculatingBiologyBiomarkers, TumorClinical RelevanceHumansRNABiomarkers, TumorCell-Free Nucleic AcidsRNABiomarkersCell-free DNACirculating tumor DNACirculating tumor RNAClinical applicationLiquid biopsyPrecision oncologyShedding mechanisms

Identifiers

PMID36681803
PMCPMC9862574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.